搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Escherichia coli O8 Nickel-responsive regulator (nikR) CSB-YP486827EOO
CSB-EP486827EOO
CSB-BP486827EOO
CSB-MP486827EOO
CSB-EP486827EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 HTH-type transcriptional regulator BetI (betI) CSB-YP486828EOO
CSB-EP486828EOO
CSB-BP486828EOO
CSB-MP486828EOO
CSB-EP486828EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 2-hydroxy-6-oxononadienedioate/2-hydroxy-6-oxononatrienedioate hydrolase (mhpC) CSB-YP486829EOO
CSB-EP486829EOO
CSB-BP486829EOO
CSB-MP486829EOO
CSB-EP486829EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Shikimate kinase 2 (aroL) CSB-YP486830EOO
CSB-EP486830EOO
CSB-BP486830EOO
CSB-MP486830EOO
CSB-EP486830EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Putative mannosyl-3-phosphoglycerate phosphatase (ECIAI1_2035) CSB-YP486831EOO
CSB-EP486831EOO
CSB-BP486831EOO
CSB-MP486831EOO
CSB-EP486831EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Cytoplasmic trehalase (treF) CSB-YP486832EOO
CSB-EP486832EOO
CSB-BP486832EOO
CSB-MP486832EOO
CSB-EP486832EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 L-seryl-tRNA (Sec) selenium transferase CSB-YP486833EOO
CSB-EP486833EOO
CSB-BP486833EOO
CSB-MP486833EOO
CSB-EP486833EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 S-adenosylmethionine:tRNA ribosyltransferase-isomerase (queA) CSB-YP486834EOO
CSB-EP486834EOO
CSB-BP486834EOO
CSB-MP486834EOO
CSB-EP486834EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Exodeoxyribonuclease 7 small subunit (xseB) CSB-YP486835EOO
CSB-EP486835EOO
CSB-BP486835EOO
CSB-MP486835EOO
CSB-EP486835EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 1- (5-phosphoribosyl)-5-[ (5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase CSB-YP486836EOO
CSB-EP486836EOO
CSB-BP486836EOO
CSB-MP486836EOO
CSB-EP486836EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Probable lipid kinase YegS (yegS) CSB-YP486837EOO
CSB-EP486837EOO
CSB-BP486837EOO
CSB-MP486837EOO
CSB-EP486837EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Deoxyuridine 5'-triphosphate nucleotidohydrolase (dut) CSB-YP486838EOO
CSB-EP486838EOO
CSB-BP486838EOO
CSB-MP486838EOO
CSB-EP486838EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Small heat shock protein ibpB (ibpB) CSB-YP486839EOO
CSB-EP486839EOO
CSB-BP486839EOO
CSB-MP486839EOO
CSB-EP486839EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Allantoinase (allB) CSB-YP486840EOO
CSB-EP486840EOO
CSB-BP486840EOO
CSB-MP486840EOO
CSB-EP486840EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Apo-citrate lyase phosphoribosyl-dephospho-CoA transferase (citX) CSB-YP486841EOO
CSB-EP486841EOO
CSB-BP486841EOO
CSB-MP486841EOO
CSB-EP486841EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 UPF0352 protein yejL (yejL) CSB-YP486842EOO
CSB-EP486842EOO
CSB-BP486842EOO
CSB-MP486842EOO
CSB-EP486842EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Membrane protein insertase YidC (yidC), partial CSB-YP486843EOO1
CSB-EP486843EOO1
CSB-BP486843EOO1
CSB-MP486843EOO1
CSB-EP486843EOO1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 ATP synthase gamma chain (atpG) CSB-YP486844EOO
CSB-EP486844EOO
CSB-BP486844EOO
CSB-MP486844EOO
CSB-EP486844EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Dihydroxy-acid dehydratase (ilvD) CSB-YP486845EOO
CSB-EP486845EOO
CSB-BP486845EOO
CSB-MP486845EOO
CSB-EP486845EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Probable UDP-N-acetyl-D-mannosaminuronic acid transferase (wecG) CSB-YP486846EOO
CSB-EP486846EOO
CSB-BP486846EOO
CSB-MP486846EOO
CSB-EP486846EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>